Last reviewed · How we verify
Cogmine (PHYSOSTIGMINE)
Physostigmine (Cogmine) is a marketed drug primarily indicated for anticholinergic toxicity, with a key composition patent expiring in 2028. Its mechanism of temporarily blocking the breakdown of acetylcholine provides a distinct therapeutic advantage in managing conditions characterized by reduced cholinergic activity. The primary risk to Physostigmine's market position is the presence of multiple off-patent competitors, including pilocarpine, carbachol, and neostigmine, which are widely available as generics.
At a glance
| Generic name | PHYSOSTIGMINE |
|---|---|
| Drug class | physostigmine |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Anticholinergic Toxicity
- Open-angle glaucoma
Common side effects
- Bradycardia
- Convulsions
- Nausea
- Vomiting
- Salivation
Key clinical trials
- Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium (PHASE2)
- Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors (NA)
- Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome (PHASE4)
- Anticholium® Per Se (NA)
- Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery (PHASE3)
- Phamacological Reversal of Airway Instability During Sedation (NA)
- Pilot Study of Physostigmine-Enhanced Opioid Analgesia (PHASE3)
- Physostigmine After General Anesthesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cogmine CI brief — competitive landscape report
- Cogmine updates RSS · CI watch RSS